EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS

  • Muhammad Sajid Hussain Army Selection & Recruitment Centre, Multan Pakistan
  • Qasim Raza Quaid-e-Azam International Hospital, Islamabad Pakistan
  • Muhammad Omer Aamir Combined Military Hospital Rawalakot/National University of Medical Sciences (NUMS) Pakistan
  • Nadia Murtaza Combined Military Hospital Peshawar/National University of Medical Sciences (NUMS) Pakistan
  • Sadia Naureen Allied Hospital, Faisalabad Pakistan
  • Mehwish Razzaq Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Keywords: Anemia, Chronic kidney disease, Erythropoietin, Hypertension

Abstract

Objective: To determine the effect of subcutaneous recombinant human erythropoietin on blood pressure in predialysis chronic kidney disease (CKD) patients.

Study Design: Case-series descriptive study.

Place and Duration of Study: Combined Military Hospital Peshawar, from Mar 2016 to Sep 2016.

Methodology: A total of 100 cases were enrolled. Inclusion criteria was patients of 18 to 60 years of both gender & estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 having Hb <10g/dL and pre-dialysis while Exclusion Criteria was pregnancy or lactation, BP more than 140/90 mmHg, patients on Haemodialysis and worsening renal function. Baseline BP, body weight and eGFR of anaemic chronic kidney disease patients were recorded prior to EPO Alpha therapy. Erythropoiesis-stimulating agents (ESAs) i.e. EPO Alpha (50-100 Units/kg thrice or once weekly) was administered subcutaneously. Subsequent blood pressure, body weight and eGFR monitoring was done after 2 and 4 weeks post EPO Alpha injection.

Results: Mean age range was 46.71 years with range of 20-60 years, 73 (73%) were male while 27 (27%) were
females. Mean ± SD for other quantitative variables like eGFR was 23.12 ± 5.28, Hb levels (g/dL) was 8.62 ± 0.85,
Weight (kg) was 56.66 ± 6.62 and duration of CKD was 9.87 ± 4.02. Frequency of Hypertension (post EPO) was 2
(2%) and p-value was 0.453.

Conclusion: We concluded that the frequency of hypertension in pre-dialysis patients with chronic kidney disease (CKD) receiving recombinant human erythropoietin (rhEPo) subcutaneously (SC) in low doses, is very low, so rhEPo can be used subcutaneously......................

Downloads

Download data is not yet available.

Author Biographies

Qasim Raza, Quaid-e-Azam International Hospital, Islamabad Pakistan

Retired as consultant Medical specialist in the rank of Lt.col. Now working as medical specialist / consultant at Quaid E Azam iinternational Hospital

Sadia Naureen, Allied Hospital, Faisalabad Pakistan

FCPS trainee 3rd year in Gyne / OBs

Mehwish Razzaq, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

Done FCPS I in Surgery . Working as trainee in Anatomy department for FCPS

Published
2021-02-24
How to Cite
Hussain, M., Raza, Q., Omer Aamir, M., Murtaza, N., Naureen, S., & Razzaq, M. (2021). EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS. PAFMJ, 71(1), 261-65. https://doi.org/10.51253/pafmj.v71i1.2489
Section
Original Articles